ArticleJournal of theoretical biology2018
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.
Article in Journal of theoretical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Article
- Advancing Tumor Treatment Through Artificial Intelligence and Mathematical Modeling: A Comprehensive Review.Health science reports · 2026Article
- Single-threshold-guided adaptive cancer therapy with partial-cycle treatment: A mechanistic and reinforcement learning analysis.PLoS computational biology · 2026Article
- Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer.International journal of radiation oncology, biology, physics · 2026Article
- Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy.NPJ systems biology and applications · 2026Article
- A Systematic Review of Evidence for the Cost of Therapeutic Resistance in Cancer.bioRxiv : the preprint server for biology · 2025Article
- Review
- Reducing phenotype-structured partial differential equations models of cancer evolution to systems of ordinary differential equations: a generalised moment dynamics approach.Journal of mathematical biology · 2025Article
- Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding.Nature communications · 2025Article
- Identifiability of phenotypic adaptation from low-cell-count experiments and a stochastic model.PLoS computational biology · 2025Article
- Estimating treatment sensitivity in synthetic and in vitro tumors using a random differential equation model.NPJ systems biology and applications · 2025Article
- Article
- Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.Clinical Medicine Insights. Oncology · 2025Review
- Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens.iScience · 2024Article
- Tumour Growth Mechanisms Determine Effectiveness of Adaptive Therapy in Glandular Tumours.Interdisciplinary sciences, computational life sciences · 2024Article
- Drug dependence in cancer is exploitable by optimally constructed treatment holidays.Nature ecology & evolution · 2024Article
- Studying mixed-species biofilms of Candida albicans and Staphylococcus aureus using evolutionary game theory.PloS one · 2024Article
- Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.Cancer research · 2023Article
- A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.eLife · 2023Article
- COVID-19 vaccine incentive scheduling using an optimally controlled reinforcement learning model.Physica D. Nonlinear phenomena · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The development of chemotherapeutic resistance resulting in tumor relapse is largely the consequence of the mechanism of competitive release of pre-existing resistant tumor cells selected for regrowth after chemotherapeutic agents attack the previously dominant chemo-sensitive population. We introduce a prisoner's dilemma game theoretic mathematical model based on the replicator of three competing cell populations: healthy (cooperators), sensitive (defectors), and resistant (defectors) cells. The model is shown to recapitulate prostate-specific antigen measurement data from three clinical trials for metastatic castration-resistant prostate cancer patients treated with 1) prednisone, 2) mitoxantrone and prednisone and 3) docetaxel and prednisone. Continuous maximum tolerated dose schedules reduce the sensitive cell population, initially shrinking tumor burden, but subsequently "release" the resistant cells from competition to re-populate and re-grow the tumor in a resistant form. The evolutionary model allows us to quantify responses to conventional (continuous) therapeutic strategies as well as to design adaptive strategies.These novel adaptive strategies are robust to small perturbations in timing and extend simulated time to relapse from continuous therapy administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.